ArticleEuropean journal of human genetics : EJHG2013
Personalized medicine and access to health care: potential for inequitable access?
Article in European journal of human genetics : EJHG, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Are There Socio-Demographic Inequalities in the Utilisation of Tumour and ctDNA Somatic Mutation Testing in Solid Tumours? A Systematic Review.Cancer medicine · 2026Pooled it
- Pooled it
- The ethical aspects of human organ-on-chip models: A mapping review.Stem cell reports · 2025Review
- Envisioning the Future of Personalized Medicine: Role and Realities of Digital Twins.Journal of medical Internet research · 2024Article
- How to translate genetic findings into clinical applications in spondyloarthritis?Frontiers in immunology · 2024Review
- Review
- Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment.Health science reports · 2023Article
- Health Technology Assessment for In Silico Medicine: Social, Ethical and Legal Aspects.International journal of environmental research and public health · 2022Review
- The role of genomics in global cancer prevention.Nature reviews. Clinical oncology · 2021Review
- Genetic Testing Consumers in Italy: A Preliminary Investigation of the Socio-Demographic Profile, Health-Related Habits, and Decision Purposes.Frontiers in public health · 2020Article
- Use of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study.Journal of clinical pathways : the foundation of value-based care · 2019Article
- Predictive, Personalized, Preventive and Participatory (4P) Medicine Applied to Telemedicine and eHealth in the Literature.Journal of medical systems · 2019Review
- Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act.Genetic testing and molecular biomarkers · 2019Article
- Ethics in genetic counselling.Journal of community genetics · 2019Review
- Article
- Achieving Equity in an Evolving Healthcare System: Opportunities and Challenges.The American journal of the medical sciences · 2016Article
- Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.European journal of human genetics : EJHG · 2014Article
- Comparison of delivery strategies for pharmacogenetic testing services.Pharmacogenetics and genomics · 2014Review
- Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.Urologic oncology · 2014Article
- Risks of nutrigenomics and nutrigenetics? What the scientists say.Genes & nutrition · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Personalized medicine promises that an individual's genetic information will be increasingly used to prioritize access to health care. Use of genetic information to inform medical decision making, however, raises questions as to whether such use could be inequitable. Using breast cancer genetic risk prediction models as an example, on the surface clinical use of genetic information is consistent with the tools provided by evidence-based medicine, representing a means to equitably distribute limited health-care resources. However, at present, given limitations inherent to the tools themselves, and the mechanisms surrounding their implementation, it becomes clear that reliance on an individual's genetic information as part of medical decision making could serve as a vehicle through which disparities are perpetuated under public and private health-care delivery models. The potential for inequities arising from using genetic information to determine access to health care has been rarely discussed. Yet, it raises legal and ethical questions distinct from those raised surrounding genetic discrimination in employment or access to private insurance. Given the increasing role personalized medicine is forecast to play in the provision of health care, addressing a broader view of what constitutes genetic discrimination, one that occurs along a continuum and includes inequitable access, will be needed during the implementation of new applications based on individual genetic profiles. Only by anticipating and addressing the potential for inequitable access to health care occurring from using genetic information will we move closer to realizing the goal of personalized medicine: to improve the health of individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.